DAVID M MOTT Insider Trading Transactions
Get free email notifications about insider trading for DAVID M MOTT.
- Your email is safe with us.
- The service is free and you can unsubscribe at any time.
General | Insider Transactions | Monthly Overview
Get the latest insider transactions of DAVID M MOTT. DAVID M MOTT is Vice Chairman and CEO in MEDIMMUNE INC /DE ($MEDI) and Director in NOVAVAX INC ($NVAX) and 10% Owner in ARCA biopharma, Inc. ($ABIO) and 10% Owner in INTERLEUKIN GENETICS INC ($ILIU) and 10% Owner in Achaogen Inc ($AKAO) and 10% Owner in AVEO PHARMACEUTICALS INC ($AVEO) and 10% Owner in MULESOFT, INC ($MULE) and 10% Owner in Tracon Pharmaceuticals, Inc. ($TCON) and 10% Owner in Cascadian Therapeutics, Inc. ($CASC) and 10% Owner in Care.com Inc ($CRCM) and Director in ARDELYX, INC. ($ARDX) and 10% Owner in APPIAN CORP ($APPN) and Director in Mersana Therapeutics, Inc. ($MRSN) and 10% Owner in GENOCEA BIOSCIENCES, INC. ($GNCA) and 10% Owner in Roka BioScience, Inc. ($ROKA) and 10% Owner in Ra Pharmaceuticals, Inc. ($RARX) and Director in TESARO, Inc. ($TSRO) and 10% Owner in Regulus Therapeutics Inc. ($RGLS) and 10% Owner in Mirna Therapeutics, Inc. ($MIRN) and 10% Owner in Cerecor Inc. ($CERC) and 10% Owner in Trevi Therapeutics, Inc. ($TRVI) and Director in Epizyme, Inc. ($EPZM) and Director in Adaptimmune Therapeutics PLC ($ADAP) and 10% Owner in RHYTHM PHARMACEUTICALS, INC. ($RYTM) and Director in IMARA Inc. ($IMRA) and 10% Owner in Elastic N.V. ($ESTC) and Director in Nightstar Therapeutics plc ($NITE) and 10% Owner in Surface Oncology, Inc. ($SURF) and 10% Owner in Mirum Pharmaceuticals, Inc. ($MIRM).
Latest Insider Trading Transactions of DAVID M MOTT
1 Week | 2 Weeks | 1 Month | 3 Months | 6 Months | 1 Year | 2 Years | |
---|---|---|---|---|---|---|---|
No. of Purchases | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Value of Purchases ($) | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
No. of Sales | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Value of Sales ($) | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Sentiment: All, AKAO, ADAP, APPN, ABIO, ARDX, AVEO, CRCM, CASC, CERC, ESTC, EPZM, GNCA, IMRA, ILIU, MEDI, MRSN, MIRM, MULE, NITE, NVAX, RARX, RGLS, RYTM, ROKA, SURF, SYBX, TSRO, TCON, TRVI
Date | Ticker | Company | Owner | Relationship | Transaction | Code | Cost ($) | Shares | Transaction Value ($) | Total Shares | % Holdings |
---|---|---|---|---|---|---|---|---|---|---|---|
Jun 22 2021 | NVAX | NOVAVAX INC | MOTT DAVID M | Director | Option Exercise | A | 0.00 | 700 | 0 | 700 | |
Jun 22 2021 | NVAX | NOVAVAX INC | MOTT DAVID M | Director | Option Exercise | A | 179.89 | 1,300 | 233,857 | 1,300 | |
Apr 01 2021 | EPZM | Epizyme, Inc. | MOTT DAVID M | Director | Grant | A | 8.71 | 2,727 | 23,752 | 153,627 | 150.9 K to 153.6 K (+1.81 %) |
Jan 20 2021 | MRSN | Mersana Therapeuti ... | MOTT DAVID M | Director | Option Exercise | A | 21.09 | 4,528 | 95,496 | 4,528 | |
Jan 05 2021 | EPZM | Epizyme, Inc. | MOTT DAVID M | Director | Grant | A | 10.86 | 2,158 | 23,436 | 88,183 | 86 K to 88.2 K (+2.51 %) |
Dec 15 2020 | MRSN | Mersana Therapeuti ... | MOTT DAVID M | Director | Buy | J | 0.00 | 486 | 0 | 9,595 | 9.1 K to 9.6 K (+5.34 %) |
Dec 15 2020 | MRSN | Mersana Therapeuti ... | MOTT DAVID M | Director | Buy | J | 0.00 | 1,096 | 0 | 9,109 | 8 K to 9.1 K (+13.68 %) |
Dec 10 2020 | ARDX | ARDELYX, INC. | MOTT DAVID M | Director | Buy | P | 5.89 | 170,000 | 1,000,841 | 417,284 | 247.3 K to 417.3 K (+68.75 %) |
Nov 12 2020 | MRSN | Mersana Therapeuti ... | MOTT DAVID M | Director | Buy | J | 0.00 | 1,112 | 0 | 6,400 | 5.3 K to 6.4 K (+21.03 %) |
Nov 12 2020 | MRSN | Mersana Therapeuti ... | MOTT DAVID M | Director | Buy | J | 0.00 | 496 | 0 | 5,288 | 4.8 K to 5.3 K (+10.35 %) |
Nov 12 2020 | MRSN | Mersana Therapeuti ... | MOTT DAVID M | Director | Buy | J | 0.00 | 496 | 0 | 4,792 | 4.3 K to 4.8 K (+11.55 %) |
Nov 12 2020 | MRSN | Mersana Therapeuti ... | MOTT DAVID M | Director | Buy | J | 0.00 | 1,106 | 0 | 4,296 | 3.2 K to 4.3 K (+34.67 %) |
Oct 01 2020 | EPZM | Epizyme, Inc. | MOTT DAVID M | Director | Grant | A | 11.93 | 1,965 | 23,442 | 86,025 | 84.1 K to 86 K (+2.34 %) |
Sep 28 2020 | EPZM | Epizyme, Inc. | MOTT DAVID M | Director | Option Exercise | A | 12.66 | 50,000 | 633,000 | 50,000 | |
Jul 01 2020 | ADAP | Adaptimmune Therap ... | MOTT DAVID M | Director | Option Exercise | A | 1.67 | 226,753 | 378,678 | 226,753 | |
Jul 01 2020 | EPZM | Epizyme, Inc. | MOTT DAVID M | Director | Grant | A | 16.06 | 1,459 | 23,432 | 84,060 | 82.6 K to 84.1 K (+1.77 %) |
Jun 29 2020 | MRSN | Mersana Therapeuti ... | MOTT DAVID M | Director | Option Exercise | A | 22.90 | 9,200 | 210,680 | 9,200 | |
Jun 26 2020 | EPZM | Epizyme, Inc. | MOTT DAVID M | Director | Buy | P | 16.03 | 62,019 | 994,165 | 82,601 | 20.6 K to 82.6 K (+301.33 %) |
Jun 26 2020 | NVAX | NOVAVAX INC | MOTT DAVID M | Director | Option Exercise | A | 83.54 | 4,400 | 367,576 | 4,400 | |
Jun 26 2020 | NVAX | NOVAVAX INC | MOTT DAVID M | Director | Option Exercise | A | 83.54 | 4,400 | 367,576 | 4,400 | |
Jun 26 2020 | ARDX | ARDELYX, INC. | MOTT DAVID M | Director | Buy | P | 6.96 | 68,373 | 476,040 | 247,284 | 178.9 K to 247.3 K (+38.22 %) |
Jun 26 2020 | ARDX | ARDELYX, INC. | MOTT DAVID M | Director | Buy | P | 6.75 | 72,598 | 489,862 | 178,911 | 106.3 K to 178.9 K (+68.29 %) |
Jun 24 2020 | ARDX | ARDELYX, INC. | MOTT DAVID M | Director | Buy | P | 6.75 | 4,673 | 31,525 | 106,313 | 101.6 K to 106.3 K (+4.60 %) |
Jun 22 2020 | EPZM | Epizyme, Inc. | MOTT DAVID M | Director | Buy | J | 0.00 | 67,662 | 0 | 106,959 | 39.3 K to 107 K (+172.18 %) |
Jun 18 2020 | NVAX | NOVAVAX INC | MOTT DAVID M | Director | Option Exercise | A | 52.15 | 8,000 | 417,200 | 8,000 | |
Jun 11 2020 | ARDX | ARDELYX, INC. | MOTT DAVID M | Director | Option Exercise | A | 7.31 | 75,000 | 548,250 | 75,000 | |
Jun 11 2020 | ARDX | ARDELYX, INC. | MOTT DAVID M | Director | Option Exercise | A | 7.31 | 23,500 | 171,785 | 23,500 | |
Jun 11 2020 | ARDX | ARDELYX, INC. | MOTT DAVID M | Director | Buy | J | 0.00 | 1,079 | 0 | 101,640 | 100.6 K to 101.6 K (+1.07 %) |
Jun 11 2020 | ARDX | ARDELYX, INC. | MOTT DAVID M | Director | Grant | A | 0.00 | 12,995 | 0 | 100,561 | 87.6 K to 100.6 K (+14.84 %) |
Jun 02 2020 | EPZM | Epizyme, Inc. | MOTT DAVID M | Director | Option Exercise | A | 17.55 | 14,013 | 245,928 | 14,013 | |
Apr 13 2020 | MRSN | Mersana Therapeuti ... | MOTT DAVID M | Director | Buy | J | 0.00 | 993 | 0 | 3,190 | 2.2 K to 3.2 K (+45.20 %) |
Apr 13 2020 | MRSN | Mersana Therapeuti ... | MOTT DAVID M | Director | Buy | J | 0.00 | 2,197 | 0 | 2,197 | 0 to 2.2 K |
Apr 09 2020 | MRSN | Mersana Therapeuti ... | MOTT DAVID M | Director | Buy | P | 5.59 | 538,599 | 3,010,768 | 538,599 | 0 to 538.6 K |
Apr 02 2020 | EPZM | Epizyme, Inc. | MOTT DAVID M | Director | Grant | A | 15.51 | 1,512 | 23,451 | 20,582 | 19.1 K to 20.6 K (+7.93 %) |
Mar 16 2020 | IMRA | IMARA Inc. | MOTT DAVID M | Director | Option Exercise | A | 16.00 | 15,457 | 247,312 | 15,457 | |
Jan 28 2020 | ADAP | Adaptimmune Therap ... | MOTT DAVID M | Director | Buy | P | 0.67 | 7,500,000 | 5,000,250 | 19,500,000 | 12 M to 19.5 M (+62.50 %) |
Jan 03 2020 | MRSN | Mersana Therapeuti ... | MOTT DAVID M | Director | Option Exercise | A | 5.36 | 19,713 | 105,662 | 19,713 | |
Jan 03 2020 | MRSN | Mersana Therapeuti ... | MOTT DAVID M | Director | Option Exercise | A | 5.36 | 19,713 | 105,662 | 19,713 | |
Dec 26 2019 | RGLS | Regulus Therapeuti ... | MOTT DAVID M | 10% Owner | Option Exercise | P | 0.00 | 900,900 | 0 | 900,900 | |
Dec 26 2019 | RGLS | Regulus Therapeuti ... | MOTT DAVID M | 10% Owner | Option Exercise | P | 0.67 | 9,009,000 | 5,999,994 | 9,009,000 | |
Dec 09 2019 | ARDX | ARDELYX, INC. | MOTT DAVID M | Director | Grant | A | 6.25 | 400,000 | 2,500,000 | 3,482,186 | 3.1 M to 3.5 M (+12.98 %) |
Oct 02 2019 | EPZM | Epizyme, Inc. | MOTT DAVID M | Director | Grant | A | 10.32 | 2,271 | 23,437 | 18,118 | 15.8 K to 18.1 K (+14.33 %) |
Jul 24 2019 | MIRM | Mirum Pharmaceutic ... | MOTT DAVID M | 10% Owner | Option Exercise | C | 0.00 | 29,889,945 | 0 | 0 | |
Jul 24 2019 | MIRM | Mirum Pharmaceutic ... | MOTT DAVID M | 10% Owner | Buy | P | 15.00 | 450,000 | 6,750,000 | 4,186,243 | 3.7 M to 4.2 M (+12.04 %) |
Jul 24 2019 | MIRM | Mirum Pharmaceutic ... | MOTT DAVID M | 10% Owner | Buy | C | 0.00 | 3,736,243 | 0 | 3,736,243 | 0 to 3.7 M |
Jul 03 2019 | ADAP | Adaptimmune Therap ... | MOTT DAVID M | Director | Option Exercise | A | 0.61 | 350,947 | 214,078 | 350,947 | |
Jun 28 2019 | EPZM | Epizyme, Inc. | MOTT DAVID M | Director | Sell | S | 12.43 | 52,473 | 652,134 | 0 | 52.5 K to 0 (-100.00 %) |
Jun 26 2019 | EPZM | Epizyme, Inc. | MOTT DAVID M | Director | Sell | S | 12.85 | 52,472 | 674,176 | 52,473 | 104.9 K to 52.5 K (-50.00 %) |
Jun 26 2019 | EPZM | Epizyme, Inc. | MOTT DAVID M | Director | Sell | S | 13.31 | 52,472 | 698,649 | 104,945 | 157.4 K to 104.9 K (-33.33 %) |
Jun 26 2019 | EPZM | Epizyme, Inc. | MOTT DAVID M | Director | Buy | J | 0.00 | 157,417 | 0 | 157,417 | 0 to 157.4 K |
Jun 26 2019 | EPZM | Epizyme, Inc. | MOTT DAVID M | Director | Buy | J | 0.00 | 38,646 | 0 | 39,297 | 651 to 39.3 K (+5,936.41 %) |
Jun 26 2019 | EPZM | Epizyme, Inc. | MOTT DAVID M | Director | Sell | J | 0.00 | 767,500 | 0 | 0 | 767.5 K to 0 (-100.00 %) |
Jun 26 2019 | EPZM | Epizyme, Inc. | MOTT DAVID M | Director | Buy | J | 0.00 | 767,500 | 0 | 767,500 | 0 to 767.5 K |
Jun 26 2019 | EPZM | Epizyme, Inc. | MOTT DAVID M | Director | Sell | J | 0.00 | 2,500,000 | 0 | 3,971,018 | 6.5 M to 4 M (-38.63 %) |
Jun 25 2019 | GNCA | GENOCEA BIOSCIENCE ... | MOTT DAVID M | 10% Owner | Buy | P | 3.50 | 2,857,142 | 9,999,997 | 7,225,676 | 4.4 M to 7.2 M (+65.40 %) |
Jun 25 2019 | GNCA | GENOCEA BIOSCIENCE ... | MOTT DAVID M | 10% Owner | Buy | P | 3.50 | 2,857,142 | 9,999,997 | 7,225,676 | 4.4 M to 7.2 M (+65.40 %) |
Jun 17 2019 | ARDX | ARDELYX, INC. | MOTT DAVID M | Director | Option Exercise | A | 2.74 | 50,000 | 137,000 | 50,000 | |
Jun 17 2019 | ARDX | ARDELYX, INC. | MOTT DAVID M | Director | Grant | A | 0.00 | 32,846 | 0 | 87,566 | 54.7 K to 87.6 K (+60.03 %) |
Jun 11 2019 | MRSN | Mersana Therapeuti ... | MOTT DAVID M | Director | Option Exercise | A | 4.31 | 25,000 | 107,750 | 25,000 | |
Jun 07 2019 | EPZM | Epizyme, Inc. | MOTT DAVID M | Director | Option Exercise | A | 13.74 | 17,633 | 242,277 | 17,633 | |
Jun 07 2019 | EPZM | Epizyme, Inc. | MOTT DAVID M | Director | Grant | A | 12.39 | 1,891 | 23,429 | 13,979 | 12.1 K to 14 K (+15.64 %) |
Jun 07 2019 | NITE | Nightstar Therapeu ... | MOTT DAVID M | Director | Option Exercise | D | 13.57 | 21,000 | 284,970 | 0 | |
Jun 07 2019 | NITE | Nightstar Therapeu ... | MOTT DAVID M | Director | Option Exercise | D | 12.27 | 36,400 | 446,628 | 0 | |
Jun 07 2019 | NITE | Nightstar Therapeu ... | MOTT DAVID M | Director | Sell | D | 25.50 | 6,662,532 | 169,894,566 | 0 | 6.7 M to 0 (-100.00 %) |
May 13 2019 | TRVI | Trevi Therapeutics ... | MOTT DAVID M | 10% Owner | Option Exercise | C | 0.00 | 17,099,315 | 0 | 0 | |
May 13 2019 | TRVI | Trevi Therapeutics ... | MOTT DAVID M | 10% Owner | Buy | P | 10.00 | 1,500,000 | 15,000,000 | 4,438,562 | 2.9 M to 4.4 M (+51.05 %) |
May 13 2019 | TRVI | Trevi Therapeutics ... | MOTT DAVID M | 10% Owner | Buy | P | 10.00 | 1,000,000 | 10,000,000 | 2,938,562 | 1.9 M to 2.9 M (+51.58 %) |
May 13 2019 | TRVI | Trevi Therapeutics ... | MOTT DAVID M | 10% Owner | Buy | C | 0.00 | 1,938,562 | 0 | 1,938,562 | 0 to 1.9 M |
May 09 2019 | RGLS | Regulus Therapeuti ... | MOTT DAVID M | 10% Owner | Option Exercise | P | 0.00 | 256,700 | 0 | 256,700 | |
May 09 2019 | RGLS | Regulus Therapeuti ... | MOTT DAVID M | 10% Owner | Option Exercise | P | 1.08 | 3,703,704 | 4,000,000 | 3,703,704 | |
May 09 2019 | RGLS | Regulus Therapeuti ... | MOTT DAVID M | 10% Owner | Buy | P | 1.08 | 1,136,704 | 1,227,640 | 2,052,454 | 915.8 K to 2.1 M (+124.13 %) |
Apr 08 2019 | AVEO | AVEO PHARMACEUTICA ... | MOTT DAVID M | 10% Owner | Option Exercise | P | 1.25 | 4,347,827 | 5,434,784 | 4,347,827 | |
Apr 08 2019 | AVEO | AVEO PHARMACEUTICA ... | MOTT DAVID M | 10% Owner | Buy | P | 1.14 | 4,347,827 | 4,956,523 | 25,243,865 | 20.9 M to 25.2 M (+20.81 %) |
Mar 06 2019 | MRSN | Mersana Therapeuti ... | MOTT DAVID M | Director | Buy | P | 4.00 | 3,750,000 | 15,000,000 | 11,890,138 | 8.1 M to 11.9 M (+46.07 %) |
Jan 29 2019 | NITE | Nightstar Therapeu ... | MOTT DAVID M | Director | Option Exercise | A | 13.57 | 21,000 | 284,970 | 21,000 | |
Jan 29 2019 | NITE | Nightstar Therapeu ... | MOTT DAVID M | Director | Option Exercise | A | 13.57 | 21,000 | 284,970 | 21,000 | |
Jan 22 2019 | TSRO | TESARO, Inc. | MOTT DAVID M | Director | Option Exercise | D | 46.89 | 7,290 | 341,828 | 0 | |
Jan 22 2019 | TSRO | TESARO, Inc. | MOTT DAVID M | Director | Option Exercise | D | 149.22 | 12,000 | 1,790,640 | 0 | |
Jan 22 2019 | TSRO | TESARO, Inc. | MOTT DAVID M | Director | Option Exercise | D | 47.27 | 12,000 | 567,240 | 0 | |
Jan 22 2019 | TSRO | TESARO, Inc. | MOTT DAVID M | Director | Option Exercise | D | 60.77 | 10,000 | 607,700 | 0 | |
Jan 22 2019 | TSRO | TESARO, Inc. | MOTT DAVID M | Director | Option Exercise | D | 26.36 | 10,000 | 263,600 | 0 | |
Jan 22 2019 | TSRO | TESARO, Inc. | MOTT DAVID M | Director | Option Exercise | D | 46.22 | 10,000 | 462,200 | 0 | |
Jan 22 2019 | TSRO | TESARO, Inc. | MOTT DAVID M | Director | Option Exercise | D | 0.00 | 4,052 | 0 | 0 | |
Jan 22 2019 | TSRO | TESARO, Inc. | MOTT DAVID M | Director | Sell | U | 75.00 | 1,333 | 99,975 | 0 | 1.3 K to 0 (-100.00 %) |
Jan 22 2019 | TSRO | TESARO, Inc. | MOTT DAVID M | Director | Sell | U | 75.00 | 739,517 | 55,463,775 | 0 | 739.5 K to 0 (-100.00 %) |
Jan 22 2019 | TSRO | TESARO, Inc. | MOTT DAVID M | Director | Sell | U | 75.00 | 9,681,038 | 726,077,850 | 0 | 9.7 M to 0 (-100.00 %) |
Jan 22 2019 | TSRO | TESARO, Inc. | MOTT DAVID M | Director | Sell | U | 75.00 | 15,362 | 1,152,150 | 0 | 15.4 K to 0 (-100.00 %) |
Jan 04 2019 | MRSN | Mersana Therapeuti ... | MOTT DAVID M | Director | Option Exercise | A | 4.31 | 25,292 | 109,009 | 25,292 | |
Dec 21 2018 | AVEO | AVEO PHARMACEUTICA ... | MOTT DAVID M | 10% Owner | Buy | P | 1.49 | 300,000 | 448,380 | 20,896,038 | 20.6 M to 20.9 M (+1.46 %) |
Dec 21 2018 | AVEO | AVEO PHARMACEUTICA ... | MOTT DAVID M | 10% Owner | Buy | P | 1.63 | 200,000 | 326,060 | 20,596,038 | 20.4 M to 20.6 M (+0.98 %) |
Dec 12 2018 | AVEO | AVEO PHARMACEUTICA ... | MOTT DAVID M | 10% Owner | Buy | P | 1.98 | 61,200 | 121,084 | 20,396,038 | 20.3 M to 20.4 M (+0.30 %) |
Dec 10 2018 | AVEO | AVEO PHARMACEUTICA ... | MOTT DAVID M | 10% Owner | Buy | P | 1.98 | 26,000 | 51,576 | 20,334,838 | 20.3 M to 20.3 M (+0.13 %) |
Dec 10 2018 | AVEO | AVEO PHARMACEUTICA ... | MOTT DAVID M | 10% Owner | Buy | P | 1.98 | 117,100 | 232,362 | 20,308,838 | 20.2 M to 20.3 M (+0.58 %) |
Dec 10 2018 | AVEO | AVEO PHARMACEUTICA ... | MOTT DAVID M | 10% Owner | Buy | P | 1.99 | 27,300 | 54,414 | 20,191,738 | 20.2 M to 20.2 M (+0.14 %) |
Nov 30 2018 | AVEO | AVEO PHARMACEUTICA ... | MOTT DAVID M | 10% Owner | Buy | P | 1.98 | 71,900 | 142,067 | 20,164,438 | 20.1 M to 20.2 M (+0.36 %) |
Nov 30 2018 | AVEO | AVEO PHARMACEUTICA ... | MOTT DAVID M | 10% Owner | Buy | P | 1.99 | 24,500 | 48,824 | 20,092,538 | 20.1 M to 20.1 M (+0.12 %) |
Nov 21 2018 | AVEO | AVEO PHARMACEUTICA ... | MOTT DAVID M | 10% Owner | Buy | P | 1.98 | 170,000 | 336,107 | 20,068,038 | 19.9 M to 20.1 M (+0.85 %) |
Nov 21 2018 | AVEO | AVEO PHARMACEUTICA ... | MOTT DAVID M | 10% Owner | Buy | P | 1.98 | 170,000 | 336,107 | 20,068,038 | 19.9 M to 20.1 M (+0.85 %) |
Nov 19 2018 | AVEO | AVEO PHARMACEUTICA ... | MOTT DAVID M | 10% Owner | Buy | P | 1.88 | 510,000 | 956,658 | 19,898,038 | 19.4 M to 19.9 M (+2.63 %) |
Nov 19 2018 | AVEO | AVEO PHARMACEUTICA ... | MOTT DAVID M | 10% Owner | Buy | P | 1.86 | 350,000 | 649,355 | 19,388,038 | 19 M to 19.4 M (+1.84 %) |
Nov 19 2018 | AVEO | AVEO PHARMACEUTICA ... | MOTT DAVID M | 10% Owner | Buy | P | 1.86 | 340,000 | 631,958 | 19,038,038 | 18.7 M to 19 M (+1.82 %) |
Oct 10 2018 | ESTC | Elastic N.V. | MOTT DAVID M | 10% Owner | Option Exercise | C | 0.00 | 1,528,117 | 0 | 0 | |
Oct 10 2018 | ESTC | Elastic N.V. | MOTT DAVID M | 10% Owner | Option Exercise | C | 0.00 | 4,155,995 | 0 | 0 | |
Oct 10 2018 | ESTC | Elastic N.V. | MOTT DAVID M | 10% Owner | Buy | C | 0.00 | 1,528,117 | 0 | 1,528,117 | 0 to 1.5 M |
Oct 10 2018 | ESTC | Elastic N.V. | MOTT DAVID M | 10% Owner | Buy | C | 0.00 | 4,155,995 | 0 | 4,155,995 | 0 to 4.2 M |
Oct 05 2018 | EPZM | Epizyme, Inc. | MOTT DAVID M | Director | Buy | P | 9.00 | 416,667 | 3,750,003 | 6,471,018 | 6.1 M to 6.5 M (+6.88 %) |
Sep 21 2018 | MRSN | Mersana Therapeuti ... | MOTT DAVID M | Director | Option Exercise | A | 12.27 | 10,000 | 122,700 | 10,000 | |
Sep 10 2018 | ADAP | Adaptimmune Therap ... | MOTT DAVID M | Director | Buy | P | 1.67 | 12,000,000 | 20,000,400 | 12,000,000 | 0 to 12 M |
Sep 10 2018 | ADAP | Adaptimmune Therap ... | MOTT DAVID M | Director | Buy | P | 1.67 | 3,000,000 | 5,000,100 | 82,978,668 | 80 M to 83 M (+3.75 %) |
Aug 22 2018 | AVEO | AVEO PHARMACEUTICA ... | MOTT DAVID M | 10% Owner | Buy | P | 2.26 | 663,716 | 1,499,998 | 18,698,038 | 18 M to 18.7 M (+3.68 %) |
Jul 20 2018 | AVEO | AVEO PHARMACEUTICA ... | MOTT DAVID M | 10% Owner | Buy | P | 2.00 | 50,600 | 101,165 | 18,034,322 | 18 M to 18 M (+0.28 %) |
Jul 20 2018 | AVEO | AVEO PHARMACEUTICA ... | MOTT DAVID M | 10% Owner | Buy | P | 1.95 | 200,000 | 390,580 | 17,983,722 | 17.8 M to 18 M (+1.12 %) |
Jul 02 2018 | EPZM | Epizyme, Inc. | MOTT DAVID M | Director | Grant | A | 13.55 | 6,088 | 82,492 | 12,088 | 6 K to 12.1 K (+101.47 %) |
Jun 28 2018 | AVEO | AVEO PHARMACEUTICA ... | MOTT DAVID M | 10% Owner | Buy | P | 2.10 | 187,130 | 392,692 | 17,783,722 | 17.6 M to 17.8 M (+1.06 %) |
Jun 28 2018 | AVEO | AVEO PHARMACEUTICA ... | MOTT DAVID M | 10% Owner | Buy | P | 2.15 | 5,295 | 11,384 | 17,596,592 | 17.6 M to 17.6 M (+0.03 %) |
Jun 26 2018 | ADAP | Adaptimmune Therap ... | MOTT DAVID M | Director | Option Exercise | A | 2.18 | 187,330 | 408,379 | 187,330 | |
Jun 15 2018 | ARDX | ARDELYX, INC. | MOTT DAVID M | Director | Option Exercise | A | 4.03 | 15,000 | 60,450 | 15,000 | |
Jun 15 2018 | ARDX | ARDELYX, INC. | MOTT DAVID M | Director | Grant | A | 0.00 | 20,843 | 0 | 54,720 | 33.9 K to 54.7 K (+61.53 %) |
Jun 05 2018 | TSRO | TESARO, Inc. | MOTT DAVID M | Director | Option Exercise | A | 0.00 | 4,052 | 0 | 4,052 | |
Jun 05 2018 | TSRO | TESARO, Inc. | MOTT DAVID M | Director | Option Exercise | A | 46.89 | 7,209 | 338,030 | 7,209 | |
Jun 05 2018 | TSRO | TESARO, Inc. | MOTT DAVID M | Director | Grant | A | 0.00 | 2,537 | 0 | 15,362 | 12.8 K to 15.4 K (+19.78 %) |
May 31 2018 | EPZM | Epizyme, Inc. | MOTT DAVID M | Director | Option Exercise | A | 17.00 | 12,500 | 212,500 | 12,500 | |
May 30 2018 | AVEO | AVEO PHARMACEUTICA ... | MOTT DAVID M | 10% Owner | Buy | P | 2.15 | 275 | 591 | 17,591,297 | 17.6 M to 17.6 M (0.00 %) |
May 30 2018 | ARDX | ARDELYX, INC. | MOTT DAVID M | Director | Grant | A | 4.00 | 416,667 | 1,666,668 | 3,082,186 | 2.7 M to 3.1 M (+15.63 %) |
May 30 2018 | ARDX | ARDELYX, INC. | MOTT DAVID M | Director | Grant | A | 4.00 | 416,666 | 1,666,664 | 3,082,186 | 2.7 M to 3.1 M (+15.63 %) |
May 21 2018 | AVEO | AVEO PHARMACEUTICA ... | MOTT DAVID M | 10% Owner | Buy | P | 2.14 | 32,200 | 69,059 | 17,591,022 | 17.6 M to 17.6 M (+0.18 %) |
May 21 2018 | AVEO | AVEO PHARMACEUTICA ... | MOTT DAVID M | 10% Owner | Buy | P | 2.14 | 20,100 | 42,928 | 17,558,822 | 17.5 M to 17.6 M (+0.11 %) |
May 21 2018 | AVEO | AVEO PHARMACEUTICA ... | MOTT DAVID M | 10% Owner | Buy | P | 2.13 | 184,179 | 391,436 | 17,538,722 | 17.4 M to 17.5 M (+1.06 %) |
May 10 2018 | AVEO | AVEO PHARMACEUTICA ... | MOTT DAVID M | 10% Owner | Buy | P | 2.13 | 70,873 | 151,250 | 17,354,543 | 17.3 M to 17.4 M (+0.41 %) |
May 09 2018 | MULE | MULESOFT, INC | MOTT DAVID M | 10% Owner | Option Exercise | C | 0.00 | 858,978 | 0 | 0 | |
May 09 2018 | MULE | MULESOFT, INC | MOTT DAVID M | 10% Owner | Option Exercise | C | 0.00 | 2,576,939 | 0 | 0 | |
May 09 2018 | MULE | MULESOFT, INC | MOTT DAVID M | 10% Owner | Option Exercise | C | 0.00 | 12,679,970 | 0 | 0 | |
May 09 2018 | MULE | MULESOFT, INC | MOTT DAVID M | 10% Owner | Sell | U | 0.00 | 858,978 | 0 | 0 | 859 K to 0 (-100.00 %) |
May 09 2018 | MULE | MULESOFT, INC | MOTT DAVID M | 10% Owner | Buy | C | 0.00 | 858,978 | 0 | 858,978 | 0 to 859 K |
May 09 2018 | MULE | MULESOFT, INC | MOTT DAVID M | 10% Owner | Sell | U | 0.00 | 2,576,939 | 0 | 0 | 2.6 M to 0 (-100.00 %) |
May 09 2018 | MULE | MULESOFT, INC | MOTT DAVID M | 10% Owner | Buy | C | 0.00 | 2,576,939 | 0 | 2,576,939 | 0 to 2.6 M |
May 09 2018 | MULE | MULESOFT, INC | MOTT DAVID M | 10% Owner | Sell | U | 0.00 | 12,679,970 | 0 | 0 | 12.7 M to 0 (-100.00 %) |
May 09 2018 | MULE | MULESOFT, INC | MOTT DAVID M | 10% Owner | Buy | C | 0.00 | 12,679,970 | 0 | 12,679,970 | 0 to 12.7 M |
Apr 23 2018 | SURF | Surface Oncology, ... | MOTT DAVID M | 10% Owner | Option Exercise | C | 0.00 | 6,995,000 | 0 | 0 | |
Apr 23 2018 | SURF | Surface Oncology, ... | MOTT DAVID M | 10% Owner | Buy | P | 15.00 | 133,333 | 1,999,995 | 3,312,877 | 3.2 M to 3.3 M (+4.19 %) |
Apr 23 2018 | SURF | Surface Oncology, ... | MOTT DAVID M | 10% Owner | Buy | C | 0.00 | 3,179,544 | 0 | 3,179,544 | 0 to 3.2 M |
Apr 23 2018 | SURF | Surface Oncology, ... | MOTT DAVID M | 10% Owner | Option Exercise | C | 0.00 | 6,995,000 | 0 | 0 | |
Apr 23 2018 | SURF | Surface Oncology, ... | MOTT DAVID M | 10% Owner | Buy | P | 15.00 | 133,333 | 1,999,995 | 3,312,877 | 3.2 M to 3.3 M (+4.19 %) |
Apr 23 2018 | SURF | Surface Oncology, ... | MOTT DAVID M | 10% Owner | Buy | C | 0.00 | 3,179,544 | 0 | 3,179,544 | 0 to 3.2 M |
Apr 10 2018 | AVEO | AVEO PHARMACEUTICA ... | MOTT DAVID M | 10% Owner | Buy | P | 2.46 | 203,200 | 499,994 | 17,283,670 | 17.1 M to 17.3 M (+1.19 %) |
Apr 10 2018 | AVEO | AVEO PHARMACEUTICA ... | MOTT DAVID M | 10% Owner | Buy | P | 2.43 | 32,100 | 78,099 | 17,080,470 | 17 M to 17.1 M (+0.19 %) |
Apr 10 2018 | AVEO | AVEO PHARMACEUTICA ... | MOTT DAVID M | 10% Owner | Buy | P | 2.24 | 685,676 | 1,536,943 | 17,048,370 | 16.4 M to 17 M (+4.19 %) |
Mar 28 2018 | ADAP | Adaptimmune Therap ... | MOTT DAVID M | Director | Buy | P | 1.92 | 6,000,000 | 11,500,200 | 79,978,672 | 74 M to 80 M (+8.11 %) |
Mar 28 2018 | ADAP | Adaptimmune Therap ... | MOTT DAVID M | Director | Buy | P | 1.90 | 571,164 | 1,087,553 | 73,978,672 | 73.4 M to 74 M (+0.78 %) |
Mar 27 2018 | TCON | Tracon Pharmaceuti ... | MOTT DAVID M | 10% Owner | Option Exercise | P | 2.70 | 707,964 | 1,911,503 | 707,964 |